FDA approves MSD’s Keytruda combinations for MIBC

The US Food and Drug Administration (FDA) has approved two of Merck & Co's (MSD) Keytruda (pembrolizumab) and Keytruda Qlex ...

The FDA Just Approved a KEYTRUDA Combination That Could Become the Standard First-Line Treatment for Aggressive Breast Cancer

Merck & Co., Inc. (NYSE:MRK) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 25, Merck & Co., Inc.
Zacks Investment Research on MSN

MRK gets EU nod for Keytruda & Padcev combination in bladder cancer

Merck MRK announced that the European Commission has approved its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), and its subcutaneous formulation, Keytruda Qlex, each in combination with ...

Merck, Pfizer, Astellas Bladder Cancer Treatment Approved by FDA

The Food and Drug Administration approved a combination treatment by Merck & Co., Pfizer, and Astellas Pharma for a hard-to-treat form of bladder cancer. The agency greenlit Merck's Keytruda and its ...
Las Vegas Sun

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

(TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV ® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody ...